Supplementary Figure S5 from Combined MEK and BCL-2/X_L Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

Abstract

<p>Supplementary Figure S5 describes the Correlation of positive predictors before and after MEK inhibition; validation of BIM as a predictor of drug response in an independent set of ovarian cancer cell lines; predictive model including baseline levels of BIM and pERK</p>